(4-benzylpiperazin-1-yl)(1H-indol-2-yl)methanone | 41717-13-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: (4-benzylpiperazin-1-yl)(1H-indol-2-yl)methanone
• 英文别名: 1-benzyl-4-(indole-2-carbonyl)-piperazine；(4-benzylpiperazin-1-yl)-(1H-indol-2-yl)methanone
• CAS: 41717-13-9
• 化学式: C₂₀H₂₁N₃O
• mdl: MFCD03839449
• 分子量: 319.406
• InChiKey: IKKXRHVVWDOOGY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  24
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  39.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  吲哚-2-羧酸 、 1-苄基哌嗪 在 4-二甲氨基吡啶 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 14.0h， 以31%的产率得到(4-benzylpiperazin-1-yl)(1H-indol-2-yl)methanone
  参考文献：
  名称：

  Investigations of SCIO-469-like compounds for the inhibition of p38 MAP kinase

  摘要：

  The p38 MAP kinase is implicated in the release of the pro-inflammatory cytokines TNF alpha and IL-1b. Inhibition of cytokine release may be a useful treatment for inflammatory conditions such as rheumatoid arthritis and Crohn's disease. A new lead structure for p38 MAP kinase inhibition was identified. Herein, we report the SAR of this new class of p38 inhibitors. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.01.023

文献信息

• Novel Benzofurans and Indols
  申请人：WELLNER Eric

  公开号：US20080119485A1

  公开（公告）日：2008-05-22

  Compounds of formula (I) wherein X is a fluorine or a chlorine atom; the methyl groups located at the 2- and 5-position of the piperazine ring are in trans-configuration to each other; Y is NH or O; R 1 is selected from hydrogen, chloro, bromo, nitro, methyl or trifluoromethyl; R 2 is selected from hydrogen, halo, methyl, trifluoromethyl, methoxy or trifluoromethoxy; or a pharmaceutically acceptable salt or solvate thereof; The invention also relates to pharmaceutical compositions containing a compound of formula (I) together with a pharmaceutically acceptable carrier. Included are also processes for the preparation of compounds of formula (I), as well as methods for treating mammals suffering from inflammatory, autoimmune, proliferative or hyperproliferative diseases by administering a compound having the formula (I) to said mammal.

  化合物的公式(I)，其中X是氟或氯原子；位于哌嗪环的2-和5-位的甲基基团相对构型为反式；Y是NH或O；R1从氢、氯、溴、硝基、甲基或三氟甲基中选择；R2从氢、卤、甲基、三氟甲基、甲氧基或三氟甲氧基中选择；或其药学上可接受的盐或溶剂；发明还涉及含有公式(I)化合物的药物组合物和制备公式(I)化合物的方法，以及通过向哺乳动物投与具有公式(I)的化合物来治疗患有炎症、自身免疫、增殖或过度增殖疾病的哺乳动物的方法。
• [EN] CONOLIDINE ANALOGUES AS SELECTIVE ACKR3 MODULATORS FOR THE TREATMENT OF CANCER AND CARDIOVASCULAR DISEASES<br/>[FR] ANALOGUES DE LA CONOLIDINE SERVANT DE MODULATEURS SÉLECTIFS D'ACKR3 POUR TRAITER LE CANCER
  申请人：LUXEMBOURG INST OF HEALTH LIH

  公开号：WO2022136486A1

  公开（公告）日：2022-06-30

  The present application discloses compounds of e.g. formulae (2), (1A), (1B) or (1C) as selective atypical chemokine receptor 3 (ACKR3) modulators for the treatment of e.g. cancer, atherosclerotic vascular disease, cardiovascular diseases, fibrosis (e.g. cardiac fibrosis), inflammatory or autoimmune diseases and conditions, conditions of excessive or abnormal vascularization (e.g. wound healing), stem cell differentiation and mobilization disorders, brain and neuronal dysfunctions (e.g. Alzheimer's disease, multiple sclerosis and demyelinating diseases), kidney dysfunction, renal dysfunction, preeclampsia, human immunodeficiency virus (HIV) infection and obesity. Further provided are said compounds for use in methods for in vitro or ex vivo diagnosis, prediction, prognosis and/or monitoring of a disease or condition characterized by an aberrant level of ACKR3 polypeptide, as well as for use in in vitro methods for identifying an agent useful as a therapeutic. An exemplary compound is e.g. WW-1.

  本申请公开了化合物的结构公式，如公式（2），（1A），（1B）或（1C），作为选择性非典型趋化因子受体3（ACKR3）调节剂，用于治疗癌症，动脉粥样硬化性血管疾病，心血管疾病，纤维化（例如心脏纤维化），炎症或自身免疫性疾病和病症，过度或异常血管化病症（例如伤口愈合），干细胞分化和移动障碍，脑和神经功能障碍（例如阿尔茨海默病，多发性硬化症和脱髓鞘性疾病），肾功能障碍，肾功能障碍，先兆子痫，人类免疫缺陷病毒（HIV）感染和肥胖症。此外，还提供了这些化合物用于体外或体外诊断、预测、预后和/或监测由ACKR3多肽水平异常特征的疾病或病症的方法，以及用于体外方法，以鉴定作为治疗药物有用的试剂。其中一个示例化合物是WW-1。
• Exploration of a new series of PAR1 antagonists
  作者：Bruno Planty、Chantal Pujol、Marie Lamothe、Catherine Maraval、Clemens Horn、Bruno Le Grand、Michel Perez

  DOI：10.1016/j.bmcl.2010.01.050

  日期：2010.3

  Two series of new PAR1 antagonists have been identified. The first incorporates a cinnamoylpiperidine motif and the second a cinnamoylpyridine pattern. The synthesis, biological activity and structure-activity relationship of these compounds are presented. In each series, one analog showed potent in vivo anti-thrombotic activity in a rat AV shunt model, with up to 53% inhibition at 1.25 mpk iv for compound 30. (C) 2010 Elsevier Ltd. All rights reserved.
• US7339059B2
  申请人：——

  公开号：US7339059B2

  公开（公告）日：2008-03-04